

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition

Céline Moison,¹ Jean-François Spinella,¹ Jalila Chagraoui,¹ Vincent-Philippe Lavallée,¹⁻⁴ Bernhard Lehnertz,¹ Clarisse Thiollier,¹ Isabel Boivin,¹ Nadine Mayotte,¹ Tara MacRae,¹ Anne Marinier,^{1,5} Josée Hébert,^{1,6-8} and Guy Sauvageau^{1,6-8}

¹The LeuceGene Project at Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada; ²Division of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, QC, Canada; ³Centre Hospitalier Universitaire Sainte-Justine Research Center, Montréal, QC, Canada; ⁴Department of Pediatrics, Faculty of Medicine, and ⁵Department of Chemistry, Université de Montréal, Montréal, QC, Canada; ⁶Institut universitaire d'hémo-oncologie et de thérapie cellulaire, Maisonneuve-Rosemont Hospital, Montréal, QC, Canada; ⁷Quebec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital Research Center, Montréal, QC, Canada; and ⁸Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada

Key Points

- *HMGA2* expression associates with immature cells in normal and leukemic context.
- Poor prognosis *HMGA2*⁺ AMLs share a unique transcriptional signature and sensitivity to G2/M inhibitors.

High-mobility group AT-hook 2 (*HMGA2*) is a nonhistone chromatin-binding protein that is normally expressed in stem cells of various tissues and aberrantly detected in several tumor types. We recently observed that one-fourth of human acute myeloid leukemia (AML) specimens express *HMGA2*, which associates with a very poor prognosis. We present results indicating that *HMGA2*⁺ AMLs share a distinct transcriptional signature representing an immature phenotype. Using single-cell analyses, we showed that *HMGA2* is expressed in CD34⁺ subsets of stem cells and early progenitors, whether normal or derived from AML specimens. Of interest, we found that one of the strongest gene expression signatures associated with *HMGA2* in AML is the upregulation of G2/M checkpoint genes. Whole-genome CRISPR/Cas9 screening in *HMGA2* overexpressing cells further revealed a synthetic lethal interaction with several G2/M checkpoint genes. Accordingly, small molecules that target G2/M proteins were preferentially active in vitro and in vivo on *HMGA2*⁺ AML specimens. Together, our findings suggest that *HMGA2* is a key functional determinant in AML and is associated with stem cell features, G2/M status, and related drug sensitivity.

Introduction

High-mobility group AT-hook 2 (*HMGA2*) is a nonhistone chromatin-binding protein known as an architectural transcriptional factor. Without any transcriptional activity of its own, *HMGA2* binds to the minor groove of AT-rich DNA sequences to alter the chromatin structure and acts, positively or negatively, on the transcription of target genes.¹ *HMGA2* regulates numerous pathways in a context-dependent manner, which include cell cycle control, DNA repair, E2F, NF-KB, transforming growth factor- β , and the epithelial–mesenchymal transition.² Although its expression is silenced in most human adult tissues,^{3,4} *HMGA2* is ubiquitously expressed during embryogenesis, where it is critical for development and cell growth. Abnormal re-expression of *HMGA2* in several solid neoplasms has been reported and is linked to chemo-resistance, advanced tumor grade, and poor prognosis.⁵⁻⁸

Submitted 26 July 2021; accepted 26 June 2022; prepublised online on *Blood Advances* First Edition 7 July 2022; final version published online 17 August 2022. DOI 10.1182/bloodadvances.2021005828.

Single-cell sequencing data of CD34⁺ cord blood cells, fresh and culture expanded, are available at the Gene Expression Omnibus data repository (accession number GSE153370). RNA-sequencing data of the CRISPR/Cas9 genome screen is available at the Gene Expression Omnibus data repository (accession number

GSE171061). The corresponding author may be contacted for other forms of data sharing (e-mail: guy.sauvageau@umontreal.ca).

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.




Figure 1.

In mouse and human hematopoiesis, *HMGA2* is preferentially expressed in hematopoietic stem and progenitor cells (HSPCs), at fetal and adult stages.^{9,10} Previous reports showed that *HMGA2* promotes expansion of myeloid progenitors¹¹ and that its overexpression in mouse bone marrow (BM) leads to a growth advantage and clonal expansion of HSPCs.¹² Overexpression of *HMGA2* in transgenic mice is also sufficient to induce tumor development, including hematologic malignancies.¹³⁻¹⁵

We previously showed that elevated *HMGA2* levels identify a subgroup of AML patients with lower frequency of complete remission, higher frequency of relapse, and resistance to induction therapy.¹⁶ We established that *HMGA2* expression predicts poor clinical outcome in AML, independently of cytogenetic risk, and that it represents a novel prognosis marker for this disease. Indeed, positivity for *HMGA2* in high-risk AML patients further decreases the prognosis to near zero, defining a very-high-risk category for which no curative therapy is available.

In this report, we studied *HMGA2* expression at the single-cell level and show that *HMGA2* is predominantly expressed in stem and early progenitors, whether normal or leukemic. Using CRISPR/Cas9 whole-genome screening, we identified vulnerabilities of *HMGA2* overexpressing leukemic cells in a cell cycle G2/M checkpoint. This finding was further confirmed *in vitro* and *in vivo* with the use of chemical inhibitors and may provide new therapeutic avenues for this poorly curable disease.

Methods

Study approval

The Leucegene project is an initiative approved by the Research Ethics Boards of Université de Montréal and Maisonneuve-Rosemont Hospital. All leukemia samples and paired normal DNA specimens were collected and characterized by the Quebec Leukemia Cell Bank after obtaining an institutional Research Ethics Board–approved protocol with informed consent according to the Declaration of Helsinki. The Quebec Leukemia Cell Bank is a biobank certified by the Canadian Tissue Repository Network.

Cytogenetic analyses and cohort definitions

Cytogenetic aberrations and composite karyotypes of the Leucegene cohort were described according to the International System for Human Cytogenomic Nomenclature 2016 guidelines.¹⁷ Complex karyotype was defined as having ≥ 3 clonal chromosomal abnormalities in the absence of World Health Organization–designated

recurrent genetic abnormalities, including t(8;21), inv(16) or t(16;16), t(9;11), t(6;9), inv(3) or t(3;3), and AML with *BCR-ABL1*.¹⁸

Whole-genome CRISPR/Cas9 screen

The extended-knockout pooled lentiviral library composed of 278 754 single-guide RNAs (sgRNAs) targeting 19 084 RefSeq genes, 3872 hypothetical open reading frames, and 20 852 alternatively spliced isoforms developed by Bertomeu et al¹⁹ was used for whole-genome CRISPR/Cas9 screen. This library, for which each gene is targeted by ~ 10 sgRNAs, was introduced within a clone of the OCI-AML5 cell line expressing a doxycycline-inducible Cas9. Cells were infected at a multiplicity of infection of 5 with *HMGA2*-YFP and control YFP lentiviral vectors (backbone, MNDU-pgk-YFP) in media supplemented with polybrene for 48 hours. Infection efficiency, determined by the percentage of YFP⁺ cells, was monitored by using flow cytometry. The extended-knockout library (kept at a minimum of 500 cells per sgRNA) was then cultured in 10% fetal bovine serum Dulbecco's modified Eagle medium supplemented with 2 $\mu\text{g}/\text{mL}$ doxycycline for a period of 7 days to induce knockouts. The infected library was maintained in culture 7 more days without doxycycline. Cell concentration and percentage of YFP⁺ cells were assessed every 2 days. Finally, genomic DNA was extracted by cell lysis in buffer containing 50 mM Tris, 50 mM EDTA, and 1% sodium dodecyl sulfate and treated with proteinase K followed by RNase and then precipitation of proteins with 7.5 M ammonium acetate and isopropanol precipitation of genomic DNA. sgRNA sequences were recovered and fitted with Illumina adaptors by polymerase chain reaction and next-generation sequencing performed on an Illumina HiSeq 2000 device as previously described.¹⁹ Resulting reads were trimmed by using Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and aligned to the sgRNA sequences by using Bowtie aligner version 2.3.3.²⁰ Synthetic rescue/positive selection and synthetic lethality/negative selection β scores, as well as statistical significance, were determined by using the MAGeCK-VISPRMAGeCK-MLE method.²¹

Primary AML sample culture and chemical screens

Freshly thawed primary AML specimens were used for chemical screens. Cryopreserved cells were thawed at 37°C in Iscove modified Dulbecco medium containing 20% fetal bovine serum and DNase I (100 $\mu\text{g}/\text{mL}$). Cells were resuspended in Iscove modified Dulbecco medium supplemented with 15% BIT (bovine serum albumin, insulin, and transferrin; Stemcell Technologies), 100 ng/mL

Figure 1 (continued) *HMGA2* is expressed in HSCs, early progenitors, and erythroid lineage. (A) Overview of hematopoietic cell populations identified in human BM from the Human Cell Atlas data set (integrated data from 8 donors, Uniform Manifold Approximation and Projection [UMAP] reduction, preprocessed data, clusters, and labels adopted from Hay et al²²). CD34⁺ HSC cluster is indicated by the black arrow. (B) UMAP plot of *HMGA2*, *CD34*, and *PCNA* expression (MAGIC imputation). (C) Single-cell transcriptomic overview of hematopoietic cell populations identified in human CB cells. Fresh and UM171-expanded CD34⁺ cells (7 days) were integrated and clustered using Seurat 3 (2 samples each condition, 15 921 cells total). Fifteen cell clusters (left) were identified and defined using Seurat (v3) procedure: HSCs, multipotent progenitors (MPP), lymphoid-primed multipotent progenitors (LMPP), granulo-monocytic progenitors (GMP), megakaryocyte-erythroid progenitors (MEP), common lymphoid progenitors (CLP), pre-dendritic cells (pre-DC), plasmacytoid dendritic cells (pDC), myeloid dendritic cells (mDC), monocytes (Mono), neutrophils (Neut), erythroid progenitors (ERP), megakaryocytes (MK), erythrocytes (Ery), and eosinophils/basophils/mast cells (Eo/Bas/Ma). Unsupervised ordering of the HSCs was done with Seurat 3 integrated results as input to build a tree-like differentiation trajectory using the DDRTree algorithm of the Monocle v3 R package (right). (D) UMAP plot of representative stem cell and lineage associated genes compared with *HMGA2* expression (integrated data from fresh and UM171-expanded CB cells, MAGIC imputation). (E) UMAP plot of representative stem cell, lineage, and proliferative genes in fresh CD34⁺ CB cells vs UM171 ex vivo expanded cells (MAGIC imputation). Red circle: non-proliferative CD34⁺ cells, orange circle: proliferative CD34⁺ FLT3⁺ progenitors. (F) Irradiated NSG mice were transplanted with CD34⁺ cells infected with short hairpin (sh) RNA green fluorescent protein (GFP) vectors targeting *HMGA2* gene or a control locus. Twenty weeks after transplantation, reconstitution was assessed by measuring the percentage of human CD45⁺ GFP⁺ cells in BM (n = 6, median is depicted, Mann-Whitney U test). Gran, granulocytes.




Figure 2.

stem cell factor (#100-04; Shenandoah Biotechnology Inc.), 50 ng/mL FLT3L (#100-21; Shenandoah Biotechnology Inc.), 20 ng/mL interleukin-3 (Shenandoah Biotechnology Inc.), 20 ng/mL granulocyte colony-stimulating factor (Shenandoah Biotechnology Inc.), 10^{-4} mol/L β -mercaptoethanol, gentamicin (50 μ g/mL), ciprofloxacin (10 μ g/mL), SR1 (500 nmol/L; Alichem), and UM729 (500 nmol/L; IRIC). Cells were plated in 384-well white plates, 5000 cells per well in 50 μ L. Compounds were dissolved in dimethyl sulfoxide (DMSO), diluted in media immediately before use, and added to seeded cells in serial dilutions (8 dilutions, 1:3, 10 μ M down to 4.5 nM for primary AML screen) in duplicate wells. The exception was daunorubicin, for which dilutions from 1 μ M to 0.45 nM were performed. Control wells received DMSO (0.1%) only. Cell viability was evaluated after 6 days in culture using the CellTiterGlo assay (Promega) according to the manufacturer's instruction. Percentage of inhibition for dose-response curves was calculated as $100 - (100 \times [\text{mean luminescence (compound)}/\text{mean luminescence (DMSO)}])$. Fifty percent inhibitory concentration (IC_{50}) values were calculated using ActivityBase SARview Suite (IDBS). Dose-response curves were generated by using nonlinear regression in GraphPad Prism version 6.01 (GraphPad Software). For cases in which compounds failed to inhibit AML cell survival/proliferation, IC_{50} values were arbitrarily reported at the highest dose tested (10 000 nM).

In vivo treatments on patient-derived xenograft models

All animal procedures complied with recommendations of the Canadian Council on Animal Care and were approved by the Deontology Committee on Animal Experimentation at the University of Montreal. NSG mice were purchased from The Jackson Laboratory and bred in a pathogen-free animal facility. Eight- to twelve-week-old female littermates were randomly assigned to experimental groups and transplanted with 2 million patient-derived xenograft (PDX) cells via the tail vein. Adverse cytogenetic AML specimens 05H179 (*EVI1* rearranged) and 09H057 (Complex Karyotype, *TP53* mutated) were chosen as relevant models because of their high *HMGA2* expression levels. Two weeks after transplantation, mice (5 mice per treatment arm per AML) were treated with volasertib (IV, 10 mg/kg, diluted in 0.9% NaCl, 2 days per week during 4 weeks), AraC (intraperitoneally, 50 mg/kg, diluted in phosphate-buffered saline, 5 days per week during 1 week), or vehicle (IV 0.9% NaCl, intraperitoneal phosphate-buffered saline). Mice were monitored daily, including weight follow-up, to assess tolerability of the treatment. BM aspirations were performed, and collected cells were analyzed by flow cytometry (BD Canto II cytometer). Percentage of leukemic cell

engraftment was assessed by using the following antibodies: anti-human CD45 Pacific Blue (#304029; BioLegend), anti-human CD33 PE (#555450; BD Biosciences), anti-human CD3 FITC (#555332; BD Biosciences), anti-human CD19 PE-Cy7 (#557835; BD Biosciences), and anti-mouse CD45.1 APC-eFluor780 (#47-0453-82; eBioscience). Results were analyzed with FlowJo software 10.7.2 (Becton, Dickinson and Company). Investigators were not blinded to treatment groups during the analysis.

Statistical analyses

Statistical differences in dot plots were determined by using the nonparametric Mann-Whitney test. Differences in response to small molecules between genetic groups were evaluated by using a Wilcoxon rank sum test performed on IC_{50} values in R version 3.1.2 (R Foundation for Statistical Computing). Graphics and statistical analysis were performed by using GraphPad Prism version 6.0.

Results

HMGA2 is expressed in hematopoietic stem cells, early progenitors, and erythroid lineage

The Human Cell Atlas single cell transcriptomic data sets of freshly isolated adult BM was first exploited to better characterize *HMGA2* expression (Figure 1A).²² Interestingly, its expression is most prevalent in a subset of $CD34^+$ hematopoietic stem cells (HSCs) (black arrow in Figure 1A-B) with low *PCNA* expression (Figure 1B), suggestive of a quiescent or low-cycling state. Accordingly, *HMGA2*-expressing cells distribute preferentially in the G1 cell cycle phase (supplemental Figure 1A). *HMGA2* expression was also observed in proliferative megakaryocyte progenitor cells ($CD34^+$), megakaryocyte-erythroid progenitor cells ($CD34^+$), early erythroblasts, and erythroblasts.

We also analyzed *HMGA2* expression by single-cell RNA-sequencing in human $CD34^+$ cells purified from cord blood (CB), either fresh or after a 7-day culture in the presence of the small molecule UM171, which is able to maintain functional HSPCs in culture.^{23,24} As found in BM $CD34^+$ populations, *HMGA2* expression in CB is mostly detected in HSPCs coexpressing *CD34*, *AVP*, and *HLF* (Figure 1C-D; supplemental Figure 1B-C). Uniform Manifold Approximation and Projection of hematopoietic hierarchy clearly shows that *HMGA2* expression markedly decreases along with differentiation, being nearly absent in mature cells at the exception of the erythroid lineage. Interestingly, the pattern of *HMGA2* expression changes upon ex vivo culture. Indeed, although *HMGA2* is markedly expressed in noncycling cells from fresh CB, its expression

Figure 2 (continued) *HMGA2*^{high} AML share an immature transcriptional signature. (A) Dot plot representation of *HMGA2* and *CD34* expression assessed by total RNA-sequencing in the Leucegene cohort of 452 primary AML specimens. Log-transformed scale is used to better visualize AMLs with low expression of these markers. Extreme AML groups of *HMGA2* expression are depicted, and dotted line defines *HMGA2* positivity threshold defined in our previous prognostic paper.¹⁶ (B) Gene Set Enrichment Analysis plot comparing *HMGA2*^{high} (RPKM >2; n = 39) vs *HMGA2* null (RPKM = 0; n = 83) transcriptomic signatures in primary AML specimens. Results obtained for EPPERT_HSC_R gene set that includes upregulated genes in HSC-enriched populations. (C) MDS constructed using expression data (100 genes presenting the largest standard deviations between samples, excluding *HMGA2*) obtained from inv(16), CK, *MLL-rearranged (MLLr)*, t(15;17), t(8;21), NPM1 mutated (N), and other subgroups, presenting either high (>2 RPKM) or null *HMGA2* expression. The subgroup denominated as "others" is composed of samples presenting none of the alterations defining the plotted groups. (D) Same analysis as in panel C with the exclusion of CK AML specimens. (E) Single-cell transcriptomic overview obtained from the integration of 5 primary AML specimen data sets from Petti et al.²⁹ Only leukemic cells, defined by the presence of at least 1 somatic mutation, are displayed. Black arrow: non-cycling *HMGA2*⁺ cells, red arrow: cycling *HMGA2*⁺ cells. Cell type annotations were adopted as published: HSC, megakaryocyte-erythroid progenitors (MEP), common myeloid progenitor (CMP), natural killer (NK), and natural killer T (NKT) (left). Uniform Manifold Approximation and Projection (UMAP) plot of *HMGA2*, stem cell, and proliferative genes (right). FDR, false discovery rate; NES, normalized enrichment score.




Figure 3. Whole-genome CRISPR/Cas9 screen identifies cell cycle regulation as a vulnerability in HMGA2-expressing cells. (A) Western blot validation of HMGA2 protein expression in Cas9 OCI-AML5 15 days after infection with HMGA2-YFP and YFP vectors. (B) After infection with HMGA2-YFP- and YFP-expressing vectors, the percentage of YFP-expressing cells was monitored by flow cytometry during the course of CRISPR/Cas9 whole-genome screen. (C) Schematic overview of the CRISPR/Cas9 whole-genome screen performed in Cas9 OCI-AML5 cells containing the Extended Knockout sgRNA library. (D) Volcano plot representing results of whole-genome CRISPR/Cas9 screen performed in OCI-AML5 cells overexpressing HMGA2 compared with YFP control vector. Most significant genes belonging to the Gene Ontology (GO) terms 1901987 (regulation of cell cycle phase transition, P value = $5.0E-16$, false discovery rate [FDR] q-value = $1.1E-13$) and 0006281 (DNA repair, P value = $1.2E-13$, FDR q-value = $1.9E-11$) that enriched in synthetic lethal interaction are depicted. *ATR*, *CHEK1*, and *WEE1* are also depicted. Asterisks indicate genes belonging to both GO terms. (E) Nonexhaustive list of significant GO terms associated with synthetic lethality in cells overexpressing HMGA2 compared with YFP control cells. (F) Gene Set Enrichment Analysis plot comparing *HMGA2* high (RPKM > 2; $n = 39$) vs *HMGA2* null (RPKM = 0; $n = 83$) transcriptomic signatures in primary AML specimens. Results obtained for G2/M checkpoint hallmark gene set. DOX, doxycycline; ER, endoplasmic reticulum; NES, normalized enrichment score.




Figure 4.

becomes more prominent in proliferative $CD34^+ FLT3^+$ progenitors in culture, concomitant with *MKI67* expression (orange vs red circles in Figure 1E and supplemental Figure 1D-E). Again, $CD34^+ AVP^+ HMGA2^+$ HSC candidates remain mostly negative for *MKI67* in cultured cells.

Matching a recent report by Kumar et al,¹⁰ we observed that *HMGA2* silencing strongly impaired human $CD34^+$ cell engraftment in mice (Figure 1F). This finding suggests that *HMGA2* is not only expressed but also essential to sustain human HSCs in vivo.

***HMGA2*^{high} AML share an immature transcriptional signature**

To assess the functional role of *HMGA2* in AML, we looked at *HMGA2* expression in the Leucegene cohort comprising 452 primary AML specimens representative of the AML subgroup diversity. *HMGA2* expression comprised between 0 and 17.1 reads per kilobase of transcript per million reads mapped (RPKM) (log transformed scale, Figure 2A), and we thus defined extreme groups of AML samples with *HMGA2* null (RPKM = 0, n = 83 or 18.4% of the cohort) or *HMGA2* high (RPKM >2, n = 39 or 8.6% of the cohort) expression. As found with normal $CD34^+$ cells, Gene Set Enrichment Analysis revealed a strong enrichment for an HSC gene signature in *HMGA2*^{high} AMLs (Figure 2B; supplemental Table 1), again indicating a stem cell-like identity associated with this gene. Multidimensional scaling (MDS) analysis also showed that specimens with high *HMGA2* expression cluster together, independently of their genetic subgroup affiliation, suggesting that a specific *HMGA2* transcriptional signature exists in AML and that *HMGA2*^{high} AML represents a distinct entity (Figure 2C-D).

We next investigated whether *HMGA2* expression in *HMGA2*^{high} AMLs was caused by cancer-related anomalies such as gene translocation, gene amplification, or 3' untranslated region (3' UTR) truncation.^{5,25-28} To address this, we analyzed the *HMGA2* locus in *HMGA2*^{high} AMLs by low-pass whole-genome sequencing and transcriptomics, and did not detect any gene amplifications (supplemental Figure 2A), fusions, or 3' UTR truncations that could explain the aberrant *HMGA2* expression observed in a subset of our AML cohort.

Interestingly, single-cell RNA-sequencing analysis of primary AMLs (from Petti et al²⁹) showed that, when expressed, *HMGA2* is restricted to a subset of $CD34^+$ leukemic cells (Figure 2E; supplemental Figure 2B). As observed in normal hematopoiesis, *HMGA2* expression in leukemic cells was observed in both noncycling cells - that coexpress the primitive marker *AVP*, lack *PCNA* expression as well as differentiation markers such as *ELANE* and *FCGR3A* (likely quiescent stem cells [black arrow in Figure 2E and supplemental Figure 2C]) - and in cycling progenitor cells (red arrow in Figure 2E and supplemental Figure 2C). Together, these data suggest that *HMGA2* expression in AML is determined by the cell of origin rather

than acquired through genetic events and points to a particular leukemia subset that originates from primitive $CD34^+$ BM cells. To support this, *HMGA2*^{high} AMLs display a *HMGA2* expression level comparable to that of primitive $CD34^+$ and $CD34^+ CD45RA^-$ human cells (supplemental Figure 2D).

Genome-wide search for vulnerabilities associated with *HMGA2* expression

HMGA2⁺ AMLs remain extremely difficult to cure,¹⁶ representing a true unmet medical need. To identify vulnerabilities linked to this AML subgroup, we turned to genome-wide approaches. First, we looked at genetic dependencies and small molecule sensitivities associated with *HMGA2* using the Cancer Dependency Map (DepMap). However, this showed poor codependencies, with the best gene (*MSRB3*) presenting a Pearson correlation of only 0.28 with *HMGA2*. Next, we engineered an AML cell line overexpressing *HMGA2* (OCI-AML5) (Figure 3A), whose proliferation was not altered by this manipulation (Figure 3B), and conducted a whole-genome CRISPR/Cas9 screen in these cells with a particular focus on synthetic lethal genes (Figure 3C). Focusing on genes conferring a growth disadvantage, several pathways with potential for therapeutic intervention were identified (Figure 3D-E; supplemental Table 2). In line with the known functions of *HMGA2* in the stability of replication forks³⁰ and telomeres,³¹ we found synthetic lethal interactions between *HMGA2* overexpression and the loss of genes involved in DNA replication and telomere maintenance. Interestingly, this genomic screen also identified synthetic lethal interactions between *HMGA2* and the loss of genes involved in cell cycle regulation and DNA repair. In particular, disruption of genes regulating cell cycle phase transition appeared critical, which is further supported by a role of *HMGA2* in maintaining genome stability.^{32,33} In line with the upregulation of a G2/M checkpoint gene signature identified in *HMGA2*^{high} primary AML specimens (Figure 3F), G2/M cell cycle phase transition was also pinpointed in this CRISPR screen.

In contrast, fewer genes were identified that conferred a growth advantage (ie, synthetic rescue) when disrupted concomitantly with *HMGA2* overexpression (supplemental Table 2). This included a known *HMGA2*-interacting partner, *PARK2* (Parkin E3 ubiquitin-protein ligase)³⁴; however, no significant enrichment for canonical pathways was observed.

G2/M checkpoint inhibitors are particularly active on *HMGA2*⁺ AMLs

To further investigate results obtained from the CRISPR/Ca9 screen, we screened a selected library of cell cycle and DNA damage protein inhibitors (Figure 4A) on 38 primary AML specimens (Figure 4B). Tested samples included complex karyotype (CK) and intermediate-risk AML specimens chosen from the Leucegene cohort according to their *TP53* and *HMGA2* status. Overall results

Figure 4 (continued) Increased sensitivity of *HMGA2*⁺ primary AMLs toward G2/M checkpoint inhibitors. (A) List of inhibitors and their primary target(s) used in the chemical screen. Genotoxic agents used as controls are not listed. (B) Repartition of the primary AML specimens selected and screen layout. Volcano plot showing the differential compound sensitivity in CK vs intermediate-risk AML specimens (C), *TP53* wild-type (WT) vs *TP53* altered AML samples (D), and CK *HMGA2*⁻ vs CK *HMGA2*⁺ samples (E). White dots represent genotoxic agents. (F) Dot plot comparison of representative ATR, CHK1, and WEE1 inhibitors between intermediate, CK *HMGA2*⁻, and CK *HMGA2*⁺ specimens (median is depicted, Mann-Whitney U test). (G) *CHEK1*, *WEE1*, *ATM*, and *CHEK2* messenger RNA expression in *HMGA2* null (RPKM = 0; n = 83) and *HMGA2* high (RPKM >2; n = 39) AML samples (median is depicted, Mann-Whitney U test). 5-FU, 5-fluorouracil; ns, not significant; PARP, poly(ADP-ribose) polymerase.




Figure 5.

showed strong antiproliferative activity of CHK1 and dual CHK1/CHK2 inhibitors on primary specimens, contrasting sharply with the lack of activity of selective CHK2 inhibitors (supplemental Figure 3A-B; supplemental Table 3). The most active compounds were also directed against ATR (VE-822), WEE1 (MK-1775), poly(ADP-ribose) polymerase (talazoparib), and phosphatidylinositol 3-kinase (PI3K; PI-103) activity, whereas ATM, DNA-dependent protein kinase (DNA-PK), CHK2, replication protein A (RPA), and broad DNA-PK/PI3K inhibitors did not show substantial activity on these primary specimens.

Comparison of sensitivity profiles of CK and intermediate-risk AML revealed no differential sensitivity to potent DNA damage inhibitors (Figure 4C). Not surprisingly, we found that *TP53*-altered specimens were more resistant to DNA-damaging agents, including drugs used in anticancer therapy (Figure 4D), and none of the DNA damage protein inhibitors were selectively active toward *TP53*-altered AML specimens. Interestingly, however, we observed that *HMGGA2*⁺ CK specimens were more sensitive to ATR, CHK1, and WEE1 inhibitors. Conversely, compounds active on CHK2, DNA-PK, poly(ADP-ribose) polymerase, RPA, and PI3K showed no specificity toward *HMGGA2*⁺ specimens (Figure 4E-F). It is worth noting that ATR and CHK1 kinases belong to the same DNA damage–signaling pathway, which is critical for DNA repair and G2/M checkpoint transition, and WEE1 acts downstream by regulating mitotic entry and integrating signals from the ATR/CHK1 checkpoint³⁵ (supplemental Figure 3C). *HMGGA2*^{high} AML specimens expressed elevated levels of *CHEK1* and *WEE1*, whereas *ATM* and *CHEK2* expression levels were not affected by *HMGGA2* status (Figure 4G). Expression of the adaptors *Claspin* and *TOPBP1* that facilitate CHK1 phosphorylation by ATR were also increased in *HMGGA2*^{high} samples without affecting ATR levels (supplemental Figure 3D). Together with the CRISPR/Cas9 screen results, our data suggest that the G2/M cell cycle transition, targeted genetically or pharmacologically, is a potential therapeutic target in *HMGGA2*⁺ AML.

HMGGA2 overexpression in cell lines modulates sensitivity to G2/M checkpoint inhibitors

Using lentiviral gene transfer, *HMGGA2* was overexpressed in several hematopoietic cell lines, including K562, OCI-AML5, and THP-1, to investigate whether manipulating *HMGGA2* levels can modulate sensitivity to G2/M checkpoint inhibitors. Of note, the impact of *HMGGA2* expression on proliferation and cell cycle profile was absent or very limited (Figure 5A-C; supplemental Figure 4A-C, 4E-G). We found that cell lines engineered to overexpress *HMGGA2* had a twofold to sevenfold increase in sensitivity to ATR and CHK1 inhibitors (Figure 5D-E; supplemental Figure 4D,H; supplemental Table 4). Importantly, results appeared p53 independent, as similar patterns were obtained using *TP53* wild-type (OCI-AML5) and *TP53*-deficient

(K562 and THP-1) cells. Overall, these results suggest that *HMGGA2* levels modulate sensitivity to G2/M checkpoint inhibitors.

In addition, we observed that *PLK1* expression is significantly higher ($P = .018$) in *HMGGA2*^{high} AML samples than in those that do not express this gene (Figure 5F). *HMGGA2* overexpression in 2 different cell lines also confers enhanced sensitivity to 2 potent polo-like kinase 1 (PLK1) inhibitors (threefold and sevenfold for volasertib and fourfold and fivefold for GSK46136) (Figure 5G-H). These data are interesting in the context that PLK1 is a key player in G2 phase and mitosis initiation³⁶ and that CK AMLs, which frequently express *HMGGA2*, are also sensitive to PLK1 inhibition.³⁷ Together, these results are consistent with the hypothesis that *HMGGA2* expression sensitizes cells to molecules that target G2/M transition.

HMGGA2^{high} PDXs are sensitive to PLK1 inhibitors in vivo

To gain insights on the in vivo response of *HMGGA2*^{high} AML to PLK1 inhibition, we transplanted 2 PDX specimens in NSG mice and monitored response to AraC and to volasertib, a clinically available and potent PLK1 inhibitor. PDX 05H179 and 09H057 were derived from an *EVI1* rearranged and a CK specimen, respectively, and both express high levels of *HMGGA2* (RPKM = 11.8 and 6). After confirmation of engraftment by PDX cells, animals were treated with AraC, volasertib, or control vehicle. For PDX 05H179 (Figure 6A-B), development of leukemia in mice was monitored by measurement of human CD45⁺ cells in BM at days 10 and 28 after the onset of treatment. Although leukemia engraftment progressed in vehicle- and AraC-treated mice, volasertib was able to contain leukemia development. For PDX 09H057 (Figure 6C-D), treatments were initiated early after transplantation and animals followed up for a long period of time to monitor the effectiveness of treatments at early stages and development of leukemia from therapy-resistant cells. At day 78 posttreatment initiation, this leukemia clearly progressed in the majority of control mice, reaching a median level of human CD45⁺ of >20% (Figure 6D). At this time point, both AraC and volasertib treatments were able to contain the disease in most animals. At 94 days' posttreatment, however, disease progression was significant in the control and AraC treatment groups, whereas the percentage of leukemia engraftment remained <1% in most of the mice treated with volasertib. These data indicate that the 4 weeks of exposure to volasertib could contain leukemia cell expansion in the majority of the mice analyzed 10 weeks' posttreatment.

Discussion

In solid tumors, gene translocation, gene amplification, or 3' UTR *HMGGA2* truncations have been reported to explain aberrant *HMGGA2* expression.^{5,25-28} In hematologic malignancies, however, only a few

Figure 5 (continued) Induced HMGGA2 expression sensitizes leukemic cells to ATR, CHK1, and PLK1 inhibitors. HMGGA2 protein expression (A), proliferation curves (B), and cell cycle analysis (C) were performed in K562 cells infected with control YFP- or HMGGA2-YFP-expressing vectors. (D) Dose-response curves and IC₅₀ values for representative ATR, CHK1 and ATR/DNA-PK/mTOR inhibitors in K562 cells infected with vectors expressing control YFP (blue) or HMGGA2-YFP (red). (E) Representation of overall chemical screen results in primary AML and cell lines (K562, OCI-AML5, and THP-1). Compounds with a significant increased activity in CK *HMGGA2*⁺ vs CK *HMGGA2*⁻ primary AML (see Figure 4E) are depicted in orange while nonsignificant compounds are in blue. In cell lines, compounds with more than a twofold decrease in IC₅₀ values in HMGGA2-expressing cells vs control are in red; others are in blue. Fold change in IC₅₀ values are indicated in corresponding boxes. (F) *PLK1* messenger RNA expression in *HMGGA2* null (RPKM = 0; n = 83) and *HMGGA2* high (RPKM >2; n = 39) AML samples (median is depicted, Mann-Whitney U test). Dose-response curves and IC₅₀ values for volasertib and GSK46136 PLK1 inhibitors in K562 (G) and THP-1 (H) cells infected with vectors expressing control YFP (blue) or HMGGA2-YFP (red). mTOR, mammalian target of rapamycin; PARP, poly(ADP-ribose) polymerase.




Figure 6. Poor prognosis *HMG2*^{high} PDXs are sensitive to PLK1 inhibitors in vivo. Summary of the treatment protocols and time point analysis for NSG mice transplanted with 2 million of 05H179 (A) or 09H057 (C) AML cells. Two weeks after transplantation, mice were treated with AraC (50 mg/kg, 5 days per week during 1 week), volasertib (10 mg/kg, 2 days per week during 4 weeks), or vehicle. BM aspiration was performed at indicated times. (B) Percentage of human CD45⁺ cells in BM at day 10 and 28 after AraC, volasertib, or vehicle treatment (n = 5, median is depicted; t test). (D) Percentage of human CD45⁺ (huCD45⁺) cells in BM at days 28, 78, and 94 after AraC, volasertib, or vehicle treatment (n = 5, median is depicted; t test). ns, not significant.

cases of chromosomal rearrangements at the *HMGA2* locus have been reported,³⁸⁻⁴¹ and none detected in our AML cohort. Rather, our data suggest that *HMGA2* expression reflects a stem cell origin or a more immature state of these leukemias. Looking at single-cell analyses, we confirmed that *HMGA2* expression in normal hematopoiesis is predominant in HSPCs, early progenitors, and the erythroid lineage.^{9,12,42} In AML, a similar pattern was observed with a marked expression of *HMGA2* in the most immature cells while absent in differentiated cell clusters. As a result of this restricted expression, *HMGA2* protein could not be detected at the protein level in bulk primary AML specimens.

Our group reported that *HMGA2* is expressed in most CK AMLs; nevertheless, elevated *HMGA2* expression can occur in a non-CK background.¹⁶ In addition, MDS-based gene expression clustering showed that *HMGA2*^{high} specimens cluster together, independent of their karyotype or genetic group, and that *HMGA2* is a prognostic marker independent of the cytogenetic risk. Altogether, these data suggest that the transcriptional regulator *HMGA2* could have an important imprint in AML and define a distinct AML identity.

HMGA2 has become an attractive therapeutic target, but due to its nature, *HMGA2* is not considered an easily druggable protein. Minor groove-binding agents such as netropsin and trabectedin displace *HMGA2* from its target promoters and achieve antitumoral activity but lack specificity.⁴³⁻⁴⁵ Targeting microRNAs⁴⁶ or downstream pathways activated by *HMGA2* represent alternative approaches to be explored. Tan et al⁴¹ indeed reported that *HMGA2* activates the PI3K/protein kinase B/mammalian target of rapamycin pathway in HL60 and NB4 cells and promotes AML proliferation. By conducting a whole-genome CRISPR/Cas9 screen in leukemic cells, we identified cell cycle regulation and DNA repair as synthetic lethal interactions with *HMGA2* overexpression. These results highlighted a vulnerability of *HMGA2* overexpressing cells toward cell cycle regulation. Accordingly, we found that the strongest gene expression signature associated with *HMGA2* in AML is the upregulation of G2/M checkpoint genes. It has also been reported that *HMGA2* interacts with the base excision repair machinery and protects cancer cells from DNA lesions induced by chemotherapeutic agents,³² and that *HMGA2* expression increases ATR/CHK1 phosphorylation in cancer cell lines and helps maintain genome stability upon DNA damage.³³ Interrogation of a DNA damage inhibitor library on primary AML specimens indeed confirmed an increased sensitivity of *HMGA2*⁺ AML to ATR, CHK1, and WEE1 inhibitors. These data suggest that *HMGA2* expression, irrespective of the *TP53* status, is of importance regarding the response to G2/M inhibitors in AML.

Together, our results showed that *HMGA2* expression in AMLs associates with the most immature leukemic cells, a distinct transcriptional profile, and sensitivity to agents targeting G2/M transition. Because some of these agents have been or are currently under evaluation in clinical trials,⁴⁷⁻⁵⁰ our results suggest that these trials may benefit from targeted subgroup analyses and in particular patients with *HMGA2*⁺ AML. The recently developed and reliable clinical test for this gene would be useful in this context.¹⁶

Acknowledgments

The authors thank Mélanie Fréchette and Valérie Blouin-Chagnon for in vivo experimentations, Muriel Draoui for project coordination,

Raphaëlle Lambert at the IRIC genomics platform for sequencing, and Jean Duchaine, Sébastien Guiral, Karine Audette, and Caroline Gauvin at the IRIC high-throughput screening platform for chemical screens. The collaboration of BCLQ (Quebec Leukemia Cell Bank) coinvestigators and the dedicated work of the BCLQ staff, namely Giovanni d'Angelo, Claude Rondeau, and Sylvie Lavallée, are also acknowledged. The authors also thank Charles-Le Moyne Hospital for providing human umbilical CB units.

This work was supported by the Government of Canada through Genome Canada and the Ministère de l'économie et de l'innovation du Québec through Génome Québec (grant 4524 and grant 13528). Support from the Leukemia Lymphoma Society and Canadian Cancer Society Research Institute to G.S. is also acknowledged. J.H. and G.S. hold a research chair from Industrielle-Alliance at Université de Montréal and a Bégin-Plouffe chair in blood stem cell chemogenomics of the Faculty of Medicine of Université de Montréal, respectively. BCLQ is supported by grants from the Cancer Research Network of the Fonds de recherche du Québec–Santé. RNA-sequencing read mapping and transcript quantification were performed on the supercomputer Briaree from Université de Montréal, managed by Calcul Québec and Compute Canada. The operation of this supercomputer is funded by the Canada Foundation for Innovation, NanoQuébec, RMGA, and the Fonds de recherche du Québec–Nature et technologies. C.M. is the recipient of a Canadian Institutes of Health Research fellowship (MFE-148251), and C.T. is supported by the Cole Foundation. V.-P.L. is the recipient of a Cole Foundation fellowship and a Vanier Canada Graduate Scholarship. J.-F.S. is supported by an IVADO (Institute for Data Valorization) and Canada First Research Excellence Fund (Apogée/CFREF) postdoctoral award and a Canadian Institutes of Health Research fellowship (MFE-158159).

Authorship

Contribution: C.M. contributed to project conception and single-cell data analysis, performed and analyzed CRISPR/Cas9 and chemical screens, generated corresponding material, and wrote the manuscript; J.-F.S. contributed to project conception, MDS, and CRISPR/Cas9 screen analyses; J.C. contributed to project conception, single-cell data analysis, and CRISPR/cas9 screen; V.-P.L. contributed to genomic and chemical screen analysis; B.L. contributed to single-cell data analysis; C.T. performed primary AML chemical screen; I.B. contributed to chemical screen and data validation; N.M. contributed to in vivo studies; T.M. contributed to CRISPR/Cas9 screen; A.M. is responsible for the chemistry team as part of the Leucegene project; J.H. selected and provided all primary AML samples and analyzed cytogenetic and clinical data; and G.S. contributed to project conception and supervision, and cowrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: J.-F.S., 0000-0003-2492-2897; V.-P.L., 0000-0001-9095-0066; A.M., 0000-0002-0116-8345.

Correspondence: Guy Sauvageau, Institute for Research in Immunology and Cancer (IRIC), PO Box 6128, Station Centre-Ville, Montreal, QC, Canada, H3C 3J7; e-mail: guy.sauvageau@umontreal.ca.

References

1. Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. *J Biol Chem*. 1990;265(15):8573-8582.
2. Mansoori B, Mohammadi A, Ditzel HJ, et al. HMGA2 as a critical regulator in cancer development. *Genes (Basel)*. 2021;12(2):269.
3. Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. *Biochim Biophys Acta*. 2001;1519(1-2):13-29.
4. Cleynen I, Van de Ven WJM. The HMGA proteins: a myriad of functions (review). *Int J Oncol*. 2008;32(2):289-305.
5. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. *Nat Genet*. 1995;10(4):436-444.
6. Xiao G, Wang X, Yu Y. CXCR4/Let-7a axis regulates metastasis and chemoresistance of pancreatic cancer cells through targeting HMGA2. *Cell Physiol Biochem*. 2017;43(2):840-851.
7. Gao X, Dai M, Li Q, Wang Z, Lu Y, Song Z. HMGA2 regulates lung cancer proliferation and metastasis. *Thorac Cancer*. 2017;8(5):501-510.
8. Mansoori B, Duijf PHG, Mohammadi A, et al. Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. *Expert Opin Ther Targets*. 2020;24(3):1-11.
9. Copley MR, Babovic S, Benz C, et al. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. *Nat Cell Biol*. 2013;15(8):916-925.
10. Kumar P, Beck D, Galeev R, et al. HMGA2 promotes long-term engraftment and myeloerythroid differentiation of human hematopoietic stem and progenitor cells. *Blood Adv*. 2019;3(4):681-691.
11. Lam K, Muselman A, Du R, et al. Hmga2 is a direct target gene of RUNX1 and regulates expansion of myeloid progenitors in mice. *Blood*. 2014;124(14):2203-2212.
12. Ikeda K, Mason PJ, Bessler M. 3' UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. *Blood*. 2011;117(22):5860-5869.
13. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. *Cancer Res*. 2000;60(15):4256-4261.
14. Efanov A, Zaneni N, Coppola V, et al. Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia. *Blood Cancer J*. 2014;4(7):e227.
15. Zaidi MR, Okada Y, Chada KK. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. *Cancer Res*. 2006;66(15):7453-7459.
16. Marquis M, Beaubois C, Lavallée V-P, et al. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia [published correction appears in *Blood Cancer J*. 2019;9(3):28]. *Blood Cancer J*. 2018;8(8):68.
17. McGowan-Jordan J, Schmid M, Simons A. International System for Human Cytogenomic Nomenclature 2016 guidelines. Basel, Switzerland: Karger; 2016.
18. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
19. Bertomeu T, Coulombe-Huntington J, Chatr-Aryamontri A, et al. A high-resolution genome-wide CRISPR/Cas9 viability screen reveals structural features and contextual diversity of the human cell-essential proteome. *Mol Cell Biol*. 2017;38(1):387.
20. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol*. 2009;10(3):R25.
21. Li W, Köster J, Xu H, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. *Genome Biol*. 2015;16(1):281.
22. Hay SB, Ferchen K, Chetal K, Grimes HL, Salomonis N. The Human Cell Atlas bone marrow single-cell interactive web portal. *Exp Hematol*. 2018;68:51-61.
23. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. *Science*. 2014;345(6203):1509-1512.
24. Chagraoui J, Girard S, Spinella J-F, et al. UM171 preserves epigenetic marks that are reduced in ex vivo culture of human HSCs via potentiation of the CLR3-KBTBD4 complex. *Cell Stem Cell*. 2021;28(1):48-62.e6.
25. Ashar HR, Fejzo MS, Tkachenko A, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. *Cell*. 1995;82(1):57-65.
26. Kazmierczak B, Wanschura S, Rosigkeit J, et al. Molecular characterization of 12q14-15 rearrangements in three pulmonary chondroid hamartomas. *Cancer Res*. 1995;55(12):2497-2499.
27. Berner JM, Meza-Zepeda LA, Kools PF, et al. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. *Oncogene*. 1997;14(24):2935-2941.
28. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev*. 2007;21(9):1025-1030.
29. Petti AA, Williams SR, Miller CA, et al. A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. *Nat Commun*. 2019;10(1):3660.

30. Yu H, Lim HH, Tjokro NO, et al. Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells. *Cell Rep*. 2014;6(4):684-697.
31. Natarajan S, Begum F, Gim J, et al. High mobility group A2 protects cancer cells against telomere dysfunction. *Oncotarget*. 2016;7(11):12761-12782.
32. Summer H, Li O, Bao Q, et al. HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. *Nucleic Acids Res*. 2009;37(13):4371-4384.
33. Natarajan S, Hombach-Klonisch S, Dröge P, Klonisch T. HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. *Neoplasia*. 2013;15(3):263-280.
34. Gao Z, Mei J, Yan X, et al. Cr (VI) induced mitophagy via the interaction of HMGA2 and PARK2. *Toxicol Lett*. 2020;333(1):261-268.
35. Raleigh JM, O'Connell MJ. The G(2) DNA damage checkpoint targets both Wee1 and Cdc25. *J Cell Sci*. 2000;113(pt 10):1727-1736.
36. Archambault V, Lépine G, Kachaner D. Understanding the polo kinase machine. *Oncogene*. 2015;34(37):4799-4807.
37. Moison C, Lavallée V-P, Thiollier C, et al. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. *Blood Adv*. 2019;3(4):552-563.
38. Kottickal LV, Sarada B, Ashar H, Chada K, Nagarajan L. Preferential expression of HMGI-C isoforms lacking the acidic carboxy terminal in human leukemia. *Biochem Biophys Res Commun*. 1998;242(2):452-456.
39. Patel HS, Kantarjian HM, Bueso-Ramos CE, Medeiros LJ, Haidar MA. Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. *Genes Chromosomes Cancer*. 2005;42(1):87-94.
40. Odero MD, Grand FH, Iqbal S, et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. *Leukemia*. 2005;19(2):245-252.
41. Tan L, Wei X, Zheng L, et al. Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML. *J Cancer Res Clin Oncol*. 2016;142(2):389-399.
42. Rowe RG, Wang LD, Coma S, et al. Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. *J Exp Med*. 2016;213(8):1497-1512.
43. Miao Y, Cui T, Leng F, Wilson WD. Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: a biosensor-surface plasmon resonance assay. *Anal Biochem*. 2008;374(1):7-15.
44. Alonso N, Guillen R, Chambers JW, Leng F. A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions. *Nucleic Acids Res*. 2015;43(8):e52.
45. D'Angelo D, Borbone E, Palmieri D, et al. The impairment of the high mobility group A (HMGA) protein function contributes to the anticancer activity of trabectedin. *Eur J Cancer*. 2013;49(5):1142-1151.
46. Cinkornpumin J, Roos M, Nguyen L, et al. A small molecule screen to identify regulators of let-7 targets. *Sci Rep*. 2017;7(1):15973.
47. Talati C, Griffiths EA, Wetzler M, Wang ES. Polo-like kinase inhibitors in hematologic malignancies. *Crit Rev Oncol Hematol*. 2016;98:200-210.
48. Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. *Blood*. 2014;124(9):1426-1433.
49. Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. *Clin Cancer Res*. 2012;18(24):6723-6731.
50. Webster JA, Tibes R, Morris L, et al. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. *Leuk Res*. 2017;61:108-116.